Half Year Result 2016 CSL Delivers Exceptional Performance

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 9%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1NPAT grew 7% and EPS grew 12%, at constant currency2.

HIGHLIGHTS

Financial
 

  • Sales US$3,056 million, up 11% on PCP 
    Underlying1 sales up 9% at constant currency2
  • NPAT US$719 million, up 4% on PCP 
    Underlying NPAT up 7% at constant currency
  • Earnings per share US$1.55, up 9% on PCP 
    Underlying EPS up 12% at constant currency
  • Cashflow from operations US$705 million, up 8% on PCP 
    Interim dividend3 of US$0.58 per share, unfranked for Australian tax purposes, payable on 15 April 2016 
    Converted to Australian currency, the interim dividend increased to approximately A$0.81 per share, up ~10% on PCP. 
     

Download this release: 
PDF icon CSL Half Year Result Announcement for 2015/16(0.2Mb)

Additional resources:
Details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast. More ...

For further information, please contact:

 

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: [email protected]
Media:
  Sharon McHale
  Senior Director Public Affairs
  CSL Limited
  Phone: +613 9389 3425
  Mobile: +614 0997 8314
  Email: [email protected]

 

Suggested Articles

The Shire bid Takeda’s been discussing is getting real. The Japanese drugmakers is gauging lender interest in financing the buy.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Daiichi Sankyo, which has struggled since losing exclusivity for its blood pressure drug Benicar, is cutting another 280 jobs in the U.S.